Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[NukeJohn]

A little Background Info for New Eyes....


I have been adding on the way down because I still believe Anatabine is the most significant medical discovery in the past decade. Although I haven't been posting much, I have still been doing research on Anatabine.

For example, in this PR from RCPI in November 2014, there was something that tweaked my curiosity.

http://investors.rockcreekpharmaceuticals.com/2014-11-10-Rock-Creek-Pharmaceuticals-Reports-Third-Quarter-2014-Results-and-Provides-Business-Update

excerpt...

The basic science associated with anatabine citrate continues to be validated and expanded. As previously disclosed, abstracts outlining four separate preclinical studies evaluating anatabine were recently accepted for poster and nano symposium presentations at the upcoming annual meeting of the Society for Neuroscience, taking place November 15-19 in Washington, DC. The presentations specifically will focus on anatabine's beneficial activity in animal models of Traumatic Brain Injury, Gulf War Illness and Alzheimer's Disease. All of these studies were independently conducted and presented by the Roskamp Institute, a not-for-profit research organization devoted to understanding neurodegenerative diseases, disorders and addictions. The studies were funded by either the Roskamp Foundation or by awards through the Congressionally Directed Medical Research Program.

Researchers from the Roskamp Institute recently published a manuscript in "Brain Disorders & Therapy," May 2014, entitled "Anatabine Attenuates Tau Phosphorylation and Oligomerization in P301S Tau Transgenic Mice." The article described how anatabine attenuated tau phosphorylation in vivo animal models which included the molecular activation inhibition of GSK3b, STAT3 and NF-kb as a proposed mechanism of action.


Why would they have put that last paragraph in the Press Release? What the heck is GSK-3b? I did a little research on GSK-3b and found a couple of interesting articles.

http://onlinelibrary.wiley.com/doi/10.1002/med.10011/abstract;jsessionid=BCD853B17B9611E8C6207AB7BD2BB1B9.f04t02

excepts...

Glycogen synthase kinase 3 (GSK-3) was initially described as a key enzyme involved in glycogen metabolism, but is now known to regulate a diverse array of cell functions. Two forms of the enzyme, GSK-3a and GSK-3ß, have been previously identified. Small molecules inhibitors of GSK-3 may, therefore, have several therapeutic uses, including the treatment of neurodegenerative diseases, diabetes type II, bipolar disorders, stroke, cancer, and chronic inflammatory disease. As there is lot of recent literature dealing with the involvement of GSK-3 in the molecular pathways of different diseases, this review is mainly focused on the new GSK-3 inhibitors discovered or specifically developed for this enzyme, their chemical structure, synthesis, and structure–activity relationships, with the aim to provide some clues for the future optimization of these promising drugs

and this article...

http://www.ncbi.nlm.nih.gov/pubmed/17504118

Abstract

Glycogen synthase kinase (GSK) was initially described as a key enzyme involved in glycogen metabolism. However, since that time it has been found to regulate a diverse range of cell functions. In addition to having a major role in the regulation of the important onco-protein beta-catenin, GSK is also a critical regulator of NF-kappaB. NF-kappaB comprises a family of transcription factors which activate the expression of a wide array of genes involved in inflammation, tumourigenesis, metastasis, differentiation, embryonic development, apoptosis. Inflammation mediated by the NF-kappaB family has been implicated in the initiation of pancreatic cancer, resistance to chemotherapy and the development of the debilitating cancer cachexia seen with advanced disease. Hence, GSK has potential as an important new target both in the treatment of resectable pancreatic cancer as an adjuvant to surgery, and in the palliation of inoperable tumours.

and this one...

http://www.hindawi.com/journals/ijcb/2012/930710/

excerpts...

Although glycogen synthase kinase-3 beta (GSK-3ß) was originally named for its ability to phosphorylate glycogen synthase and regulate glucose metabolism, this multifunctional kinase is presently known to be a key regulator of a wide range of cellular functions. GSK-3ß is involved in modulating a variety of functions including cell signaling, growth metabolism, and various transcription factors that determine the survival or death of the organism. Secondary to the role of GSK-3ß in various diseases including Alzheimer’s disease, inflammation, diabetes, and cancer, small molecule inhibitors of GSK-3ß are gaining significant attention. This paper is primarily focused on addressing the bifunctional or conflicting roles of GSK-3ß in both the promotion of cell survival and of apoptosis. GSK-3ß has emerged as an important molecular target for drug development.

Anybody know of a small molecule that inhibits GSK-3b? Oh yeah...it's called Anatabine. Anyone know of a small molecule that inhibits inflamation due to NF-kB and crosses the blood brain barrier? Oh yeah, it's called Anatabine. One day the world will know and people will be wishing they bought RCPI at prices below $3.

RCPI's new management appears to be focused on the science...and ultimately, that will pay dividends. In the meantime, I have been taking advantage of this extraordinary opportunity. I know it works because I have been taking it for over three and half years, and I know dozens of others who have a new life because of Anatabine. I managed to get my hands on some more, so I now have enough to last for a while.

Let's watch what happens as it continues to climb. When it gets over $5, I think there are some mutual funds and other institutions on the sidelines that will finally be able to buy.

JMHO,

NJ